Related Experiment Video
Updated: Oct 4, 2025
03:20
Studying Chronic Exposure of Mice to Ultraviolet B Radiation
Published on: August 19, 2025
1.2K
Systemic therapies in vitiligo: a review
Sakeena Fatima1, Tazeen Abbas2, Maggi A Refat3
1Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
International Journal of Dermatology
|February 8, 2022
Summary
Vitiligo treatment faces challenges with topical therapies. Systemic agents offer new options for extensive depigmentation, improving patient outcomes and quality of life.
Area of Science:
- Dermatology
- Immunology
Background:
- Vitiligo presents as depigmented macules and patches.
- Autoimmunity is a key factor in vitiligo pathogenesis.
- Topical immunosuppressants are common but often inefficient for extensive disease.
Purpose of the Study:
- To review systemic agents for vitiligo treatment.
- To address challenges with current topical therapies.
- To provide clinicians with additional therapeutic options for vitiligo.
Main Methods:
- Literature review of systemic therapies for vitiligo.
- Analysis of current treatment guidelines and emerging research.
- Discussion of efficacy and safety profiles of systemic agents.
Main Results:
- Systemic therapies are gaining interest for vitiligo management.
- Oral therapies are underutilized due to safety and efficacy concerns.
- Systemic agents may offer improved outcomes for extensive vitiligo.
Conclusions:
- Prompt and aggressive vitiligo treatment is crucial.
- Systemic agents represent a promising therapeutic avenue.
- Further research is needed to clarify the role of systemic therapies.
